Ad
AFMD Short Information Affimed N.V.
home / stock / afmd / afmd short
Short Information | Affimed N.V. (NASDAQ:AFMD)
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 1,748,557 |
| Total Actual Volume | 7,268,664 |
| Short Trends | |
|---|---|
| Cover Days | 19 |
| Short Days | 0 |
| No Change Days | 1 |
| Averages | |
|---|---|
| Average Short Volume | 87,428 |
| Average Short Percentage | 23.56% |
Is there a AFMD Short Squeeze or Breakout about to happen?
See the AFMD Short Analysis for free Sign up or Login
Powered by Squeeze Report
AFMD Twenty Trading Day's Volume to Short Volume Chart
AFMD Twenty Trading Day Price Chart
AFMD Short Data Results Days
| Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 01-17-2025 | $1.1 | $1.15 | $1.16 | $1.05 | 347,195 | 66,968 | 19.29% |
| 01-16-2025 | $1.09 | $1.08 | $1.14 | $1.03 | 433,961 | 125,819 | 28.99% |
| 01-15-2025 | $1.09 | $1.08 | $1.15 | $1.06 | 205,209 | 73,248 | 35.69% |
| 01-14-2025 | $1.16 | $1.07 | $1.16 | $1.055 | 255,600 | 68,859 | 26.94% |
| 01-13-2025 | $1.16 | $1.12 | $1.16 | $1.075 | 229,440 | 40,281 | 17.56% |
| 01-10-2025 | $1.19 | $1.18 | $1.2091 | $1.14 | 192,192 | 45,372 | 23.61% |
| 01-08-2025 | $1.3 | $1.19 | $1.3292 | $1.18 | 291,698 | 83,616 | 28.67% |
| 01-07-2025 | $1.35 | $1.32 | $1.3894 | $1.31 | 287,061 | 76,483 | 26.64% |
| 01-06-2025 | $1.37 | $1.36 | $1.41 | $1.34 | 208,111 | 28,214 | 13.56% |
| 01-03-2025 | $1.37 | $1.36 | $1.38 | $1.31 | 224,309 | 36,485 | 16.27% |
| 01-02-2025 | $1.26 | $1.35 | $1.54 | $1.2401 | 797,435 | 196,044 | 24.58% |
| 12-31-2024 | $1.24 | $1.19 | $1.2993 | $1.19 | 312,194 | 101,983 | 32.67% |
| 12-30-2024 | $1.32 | $1.24 | $1.32 | $1.21 | 352,096 | 79,570 | 22.6% |
| 12-27-2024 | $1.27 | $1.29 | $1.3292 | $1.2602 | 265,430 | 64,509 | 24.3% |
| 12-26-2024 | $1.22 | $1.27 | $1.33 | $1.2102 | 225,855 | 49,261 | 21.81% |
| 12-24-2024 | $1.2 | $1.24 | $1.25 | $1.16 | 251,918 | 27,463 | 10.9% |
| 12-23-2024 | $1.19 | $1.19 | $1.23 | $1.16 | 384,489 | 86,344 | 22.46% |
| 12-20-2024 | $1.18 | $1.19 | $1.25 | $1.1438 | 419,310 | 106,072 | 25.3% |
| 12-19-2024 | $1.29 | $1.18 | $1.29 | $1.15 | 773,947 | 182,844 | 23.62% |
| 12-18-2024 | $1.44 | $1.26 | $1.5 | $1.18 | 811,214 | 209,122 | 25.78% |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
In 33 heavily pretreated NSCLC EGFR wild-type ( EGFR wt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting confirmatory scan) and a disease control rate (DCR) of 76%; tumor shrinkage was observed in 4...
-
AFM28, a bispecific, tetravalent innate cell engager (ICE ® ) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients AFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infu...
-
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conferen...